Overview
Drug-resistant tuberculosis (DR-TB) refers to tuberculosis caused by Mycobacterium tuberculosis strains that are resistant to at least one of the first-line anti-tuberculosis drugs, posing significant therapeutic challenges and public health concerns 1.Diagnosis
Initial Tests: Nucleic acid amplification techniques (rapid genotypic tests) are recommended for detecting the M. tuberculosis genome and rifampicin resistance 1.
Microbiological Confirmation: Sputum smear microscopy and culture remain essential for definitive diagnosis 1.
Genotypic Testing: Essential for identifying specific drug resistance patterns 1.Management
First-Line Treatment: Involves second-line drugs such as fluoroquinolones, injectable agents (e.g., amikacin, kanamycin, capreomycin), and bedaquiline or delamanid 1.
Adjunctive Therapies: Management may include corticosteroids for severe forms like MDR-TB with extensive lung cavitation 1.
Monitoring: Regular monitoring for adverse effects, particularly ototoxicity from aminoglycosides, is crucial 4.Special Populations
Pregnancy: Specific guidelines for managing DR-TB in pregnant women are not detailed in the provided abstracts 1.
Pediatrics: Management strategies for pediatric patients with DR-TB are not explicitly covered 1.
Elderly: Considerations for elderly patients are not addressed in the abstracts 1.
Comorbidities: Management adjustments for patients with comorbidities like HIV are not specified 1.Key Recommendations
Utilize nucleic acid amplification techniques for initial detection of M. tuberculosis and rifampicin resistance (Evidence: Strong) 1.
Incorporate rapid genotypic tests to identify specific drug resistance patterns in DR-TB patients (Evidence: Strong) 1.
Regularly monitor patients for aminoglycoside-induced ototoxicity during treatment (Evidence: Moderate) 4.
Consider the use of second-line drugs including fluoroquinolones and injectable agents in the treatment regimen (Evidence: Moderate) 1.
Evaluate and manage adverse effects, particularly focusing on hearing loss associated with aminoglycoside use (Evidence: Moderate) 4.References
1 Sanchez-Montalva A, Caminero JA, Guna MR, Sanz TR, Rabuñal R, Millet JP et al.. Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Archivos de bronconeumologia 2024. link
2 Makridis KL, Kaindl AM. Real-world experience with cenobamate: A systematic review and meta-analysis. Seizure 2023. link
3 Dawgiałło M, Zasztowt-Sternicka M, Jagielska A, Kuthan R, Kanecki K, Nitsch-Osuch A. Colonization with drug-resistant pathogens among patients in long-term care facilities and under home hospice care - a cross-sectional study. Annals of agricultural and environmental medicine : AAEM 2023. link
4 Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review. The Journal of infection 2021. link